富血小板血浆与透明质酸联合及单纯透明质酸治疗膝骨关节炎的临床疗效并MRI分析:一项随机对照试验
Clinical Efficacy of Platelet-Rich Plasma and Hyaluronic Acid Versus Hyaluronic Acid for Knee Osteoarthritis with MRI Analysis: A Randomized Controlled Trial.
作者信息
Zhang Mandy, Chew Kelvin, Goh Patrick, Tun Mon Hnin, Sheah Kenneth, Tan Victor, Lim Baoying, Ng Chung Sien, Tan Benedict
机构信息
SingHealth Duke-NUS Sport and Exercise Medicine Centre, Changi General Hospital, Singapore 529889, Singapore.
Sports Medicine International, Singapore 258500, Singapore.
出版信息
J Clin Med. 2025 May 19;14(10):3553. doi: 10.3390/jcm14103553.
Some evidence suggests that combining hyaluronic acid (HA) with platelet-rich-plasma (PRP) may offer synergistic benefits by enhancing the biological and mechanical properties of joints. However, data on the combination of HA+PRP vs. HA alone in the management of knee osteoarthritis (OA) remain limited. A double-blinded randomized controlled trial was conducted at an outpatient clinic and enrolled 58 patients with Kellgren-Lawrence grade 2-3 knee OA. They were randomly allocated to receive either intra-articular PRP combined with HA ( = 29 knees) or HA alone ( = 29 knees). The primary outcome was pain, assessed using a visual analog scale (VAS). Secondary outcomes included the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), health-related quality of life (EQ-5D-5L), and structural changes on MRI, measured by the Whole-Organ MRI Score (WORMS). The VAS, WOMAC, and EQ-5D-5L were evaluated at baseline and at months 1, 3, 6, and 12. MRI WORMS was assessed at baseline and 12 months. : The baseline characteristics were comparable between the HA+PRP and HA groups. Both interventions showed improvements in pain and function at 12 months. However, the between-group difference in VAS at 12 months-the primary outcome-was not statistically significant ( = 0.102) and did not exceed the minimal clinically important difference (MCID) of 20 mm. The HA group demonstrated significantly greater VAS score reductions at 1 month (-31.1 [95% CI: -38.9 to -23.2] vs. -14.3 [95% CI: -22.2 to -6.4], = 0.003) and at 6 months (-32.1 [95% CI: -40.1 to -24.1] vs. -19.2 [95% CI: -27.1 to -11.3], = 0.024), compared to the HA+PRP group, although these differences did not reach clinical significance. No significant between-group differences were observed in the WOMAC scores, EQ-5D-5L, or total WORMS scores at all time points ( > 0.05). At 12 months, MRI assessment revealed a significant decrease in bone marrow edema in the HA+PRP group (-0.7 [95% CI: -1.6 to 0.2]) compared to the HA group (0.7 [95% CI: -0.2 to 1.6], = 0.030). : Both HA+PRP and HA treatments were effective in reducing pain and improving function in patients with knee OA over 12 months. While HA demonstrated greater early pain relief, the addition of PRP was associated with a significant reduction in bone marrow edema at 12 months. These findings suggest potential structural benefits of HA+PRP, although clinical superiority over HA alone was not established.
一些证据表明,将透明质酸(HA)与富血小板血浆(PRP)联合使用,可能通过增强关节的生物学和力学性能而产生协同效益。然而,关于HA + PRP与单独使用HA治疗膝关节骨关节炎(OA)的数据仍然有限。在一家门诊诊所进行了一项双盲随机对照试验,招募了58例Kellgren - Lawrence 2 - 3级膝关节OA患者。他们被随机分配接受关节腔内注射PRP联合HA(n = 29膝)或单独使用HA(n = 29膝)。主要结局指标是疼痛,采用视觉模拟量表(VAS)进行评估。次要结局指标包括西安大略和麦克马斯特大学骨关节炎指数(WOMAC)、健康相关生活质量(EQ - 5D - 5L)以及MRI上的结构变化,通过全器官MRI评分(WORMS)进行测量。在基线以及第1、3、6和12个月时评估VAS、WOMAC和EQ - 5D - 5L。在基线和12个月时评估MRI WORMS。结果:HA + PRP组和HA组之间的基线特征具有可比性。两种干预措施在12个月时均显示出疼痛和功能改善。然而,12个月时的主要结局指标VAS组间差异无统计学意义(P = 0.102),且未超过20 mm的最小临床重要差异(MCID)。与HA + PRP组相比,HA组在第1个月(-31.1 [95% CI:-38.9至-23.2] 对 -14.3 [95% CI:-22.2至-6.4],P = 0.003)和第6个月(-32.1 [95% CI:-40.1至-24.1] 对 -19.2 [95% CI:-27.1至-11.3],P = 0.024)时VAS评分降低幅度显著更大,尽管这些差异未达到临床显著性。在所有时间点,WOMAC评分、EQ - 5D - 5L或总WORMS评分组间均未观察到显著差异(P > 0.05)。在12个月时,MRI评估显示HA + PRP组的骨髓水肿显著减少(-0.7 [95% CI:-1.6至0.2]),而HA组为0.7 [95% CI:-0.2至1.6],P = 0.030。结论:HA + PRP和HA治疗在12个月内均能有效减轻膝关节OA患者的疼痛并改善功能。虽然HA在早期疼痛缓解方面表现更佳,但添加PRP与12个月时骨髓水肿的显著减少相关。这些发现提示了HA + PRP潜在的结构益处,尽管未确立其相对于单独使用HA的临床优越性。